Hepalink-Backed HighTide Bets On NASH For Global Markets

Emerging Company Profile: Fatty liver disease has been a hot development area that keeps getting more attention, and one Chinese startup backed by the world’s largest heparin manufacturer is looking to launch a new therapy globally.

Emerging Company Profile Regular column feature image Version 2
HighTide Obtains Fast-Track Designations For NASH and PSC Compounds

When Liping Liu returned to China looking to start up a drug discovery firm, the first thing she did was to consult with those who have had success in the field.

One of the executives she interviewed was the CEO of Betta Pharmaceuticals Co. Ltd

China Unbound: First In A Series

China has seen explosive growth in developing new drugs, ranging from antibodies to cell therapies, and this is the first in a mini series of profiles of emerging bioventures in China

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from China

More from Focus On Asia